Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland

• Váldodahkkit: Arjun Bhadhuri (Dahkki), Daniel Dröschel (Dahkki), Mike Guldimann (Dahkki), Claudia Jetschgo (Dahkki), Judit Banhazi (Dahkki), Matthias Schwenkglenks (Dahkki), C. Simone Sutherland (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: BMC, 2022-06-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Objective We aimed to evaluate the cost-effectiveness of voretigene neparvovec (VN) compared with standard of care (SoC) for patients with inherited retinal disease (IRD) caused by a biallelic RPE65-mutation. VN is a live, non-replicating adeno-associated virus serotype 2 (AAV2). SoC is bes...